<ArticleSet>
<Article>
<Journal>
<PublisherName>Pharmaceutical and Biological Evaluations</PublisherName>
<JournalTitle>Pharmaceutical and Biological Evaluations</JournalTitle>
<Issn>2394-0859</Issn>
<Volume>4</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2017</Year>
<Month>06</Month>
<Day>01</Day>
</PubDate>
</Journal>
<ArticleTitle>Formulation and evaluation of orodispersible tablet of ivabradine hydrochloride</ArticleTitle>
<FirstPage>162</FirstPage>
<LastPage>170</LastPage>
<Language>EN</Language>
<AuthorList>
<Author>
<FirstName>D.</FirstName>
<MiddleName>B.</MiddleName>
<LastName>Patel</LastName>
<Affiliation>Department of Pharmaceutical Technology, Ratnamani College of Pharmacy, Shankhalpur, Gujarat. pdhaval327@gmail.com</Affiliation>
</Author>
<Author>
<FirstName>K.</FirstName>
<MiddleName>J.</MiddleName>
<LastName>Patel</LastName>
</Author>
<Author>
<FirstName>P.</FirstName>
<MiddleName>D.</MiddleName>
<LastName>Bharadia</LastName>
</Author>
</AuthorList>
<History>
<PubDate>
<Year>2017</Year>
<Month>04</Month>
<Day>14</Day>
</PubDate>
<PubDate>
<Year>2017</Year>
<Month>04</Month>
<Day>24</Day>
</PubDate>
<PubDate>
<Year>2017</Year>
<Month>04</Month>
<Day>22</Day>
</PubDate>
</History>
<Abstract>Objective: The objective of present research work was to develop formulation of orodispersible tablets of Ivabradine HCl and evaluate it for different evaluation parameters.Methods: The tablets were prepared by direct compression method. The formulation of the tablets were evaluated before compression for characterization of flow properties and after compression for different parameters of orodispersible tablet formulation.Results: Ivabradine hydrochloride orodispersible tablets were developed with considerable increase in drug release as compared to marketed formulations; nine formulations were developed and studied. The difference in drug release values was found to be 100.88 ± 0.10 respectively. The drug was characterized according to different compendial methods, on the basis of identification by HPLC, pH, organoleptic properties and other tests. Parameters evaluated were within prescribed limits and indicated good free flowing properties. The F6 batch with disintegration time 21 ± 3.0 and dissolution 99.29% was selected as optimized formulation. This was compared with conventional marketed formulation and was found superior. Batch F6 was also subjected to stability studies for two months and was tested for its hardness, wetting time, disintegration time, drug contents and dissolution behaviour monthly.Conclusions: By appropriate selection of excipients, it was possible to develop orodispersible tablets of Ivabradine HCl.</Abstract>
<ObjectList>
<Object>
<Param>Orodispersible tablets, Ivabradine HCl, Superdisintegrants, Direct compression</Param>
</Object>
</ObjectList>
<URLs>

Abstract

<Fulltext>
<pdf>http://onlinepbe.com/index.php/PBE/article/view/235/pdf</pdf>
</Fulltext>
</URLs>
</Article>
</ArticleSet>

Refbacks

  • There are currently no refbacks.




Copyright (c) 2017 Pharmaceutical and Biological Evaluations

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.



Creative Commons License

 

© Copyright 2017 - Pharmaceutical and Biological Evaluations